BioVaxys Technology Corp. and SpayVac-for-Wildlife have expanded their existing license agreement to include commercial aquaculture and farm-raised fish markets, significantly increasing the potential global revenue for their fertility control vaccine technology.
The expanded agreement allows SpayVac to develop and market no-booster fertility-control vaccines specifically designed for aquaculture. The breakthrough offers fish producers an alternative to triploidy, a genetic manipulation technique currently used to induce sterility in farmed fish.
Thomas D'Orazio, CEO of SpayVac-for-Wildlife, highlighted the strategic importance of the development, noting that the single-dose immunocontraceptive approach provides producers with a scalable and cost-effective reproductive control solution for farmed fish.
This expansion builds upon SpayVac's existing market for contraceptive vaccines in feral, wild, invasive, and select production and companion animals. By entering the aquaculture sector, the company potentially creates new opportunities for vaccine sales across a global market.
The partnership leverages BioVaxys' patented liposome-based delivery platform, which has previously been licensed to companies like Zoetis Inc. for animal health applications. This technological foundation could provide a competitive advantage in developing innovative reproductive control solutions for various animal populations.
